journal cover

Safety considerations in the pharmacological management of atrial fibrillation

International Journal of Cardiology

Jan 15, 2008

A John Camm

Abstract

The pharmacological management of atrial fibrillation (AF) requires careful consideration from a safety perspective. This article focuses primarily on maintenance therapy using antiarrhythmic drugs (AADs). The foremost safety issue for AADs is the propensity of class IA and III agents t...read more

Mentioned in this Paper

Ventricular Fibrillation
Azimilide
Calcium [EPC]
Meta-Analysis (Publications)
Creatinine Clearance Measurement
Disopyramide
Bradycardia
Enzymes, antithrombotic
Calcium
Amiodarone
Paper Details
References
  • References46
  • Citations32
12345
  • References46
  • Citations32
1234

Similar Papers Found In These Feeds

Supraventricular Arrhythmias

Supraventricular arrhythmias are abnormal heart rhythms, typically faster than normal rhythms, that originate in the upper part of the heart. Find the latest research on supraventricular arrhythmias here.

Coronary Artery Disease

Coronary artery disease is extremely prevalent in western societies and is the number one cause of morbidity and mortality industrialized countries. Known risk factors include hypertension, smoking and dyslipidemia. Discover the latest research on coronary artery disease here.

Ventricular Arrhythmias

Ventricular arrhythmias are abnormal heart rhythms that originate in the lower part of the heart. Find the latest research on ventricular arrhythmias here.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Omics in Myocardial Infarction

Omics are used to understand the gene expression profile and proteomics of many diseases. This feed focuses on the omics of myocardial infarction and heart failure. Here are the latest discoveries pertaining to this disease.

Heart Rhythm & Arrythmias

Heart arrhythmias, also known as irregular heartbeat or cardiac dysrhythmia, are a group of conditions where the heartbeat is irregular (dysrhythmia), too slow (bradycardia), or too fast (tachycardia). Discover the latest research on heart rhythm and arrythmias here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

HFrEF

Heart failure with reduced ejection fraction (HF-rEF) is responsible for high costs and increased rates of hospital admissions along with high mortality and morbidity risks. Only treatment for HF-rEF has been shown to be efficacious compared to HF-pEF which currently has no useful treatment options. Here is the latest research on HF-rEF.

Inotropic Agents & Heart Disease

Inotropic agents alter the force or energy of muscular contractions. Negatively inotropic agents weaken the force of muscular contractions. Positively inotropic agents increase the strength of muscular contraction. Inotropic agents are used in hospitalized patients with acute decompensated heart failure, with reduced left ventricular ejection fraction and with signs of end-organ dysfunction in the setting of a low cardiac output, or with severe systolic heart failure awaiting heart transplant to maintain hemodynamic stability or as a bridge to decision. Discover the latest research on inotrpic agents and heart diseases here.

HFpEF

HF-pEF is associated with left ventricular diastolic dysfunction and concentric left ventricular hypertrophy and has significant mortality and morbidity. The heterogeneity of the disease has resulted in the failure of any drugs for the treatment of HF-pEF. Here are the latest discoveries pertaining to this disease.

Cardiac Conduction System

The cardiac conduction system is a specialized tract of myocardial cells responsible for maintaining normal cardiac rhythm. Discover the latest research on the cardiac conduction system here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Selective Ion Transport in Channels & Pumps

Ion channels and pumps are central to a number of cell functions, including membrane excitability and synaptic transmission. With sophisticated imaging, these channels and pumps have been characterized as selective for the ions, sodium, potassium chloride and calcium. Here is the latest research on selection ion transport in channels and pumps.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Bradyarrhythmias

Bradyarrhythmias are slow heart rates. Symptoms may include syncope, dizziness, fatigure, shortness of breath, and chest pains. Find the latest research on bradyarrhythmias here.

Mechanisms of CYP450

Cytochrome P450 (CYP450) are a family of enzymes involved in two major processes, such as the synthesis of fatty acids, steroids, and biles acids, and the metabolism of toxins and drugs. Discover the latest research on the Mechanisms of CYP450 enzymes here.

Coronary Artery Aneurysm

Coronary artery aneurysms are the dilation of the coronary arteries that supply the heart tissue with blood and nutrients. The dilation exceeds 1.5 times the normal artery size. Complications can occur if these aneurysms rupture. Here is the latest research on coronary artery aneurysms.

Related Papers

The New England Journal of Medicine

Drug-induced prolongation of the QT interval

The New England Journal of MedicineJune 18, 2004
Panagiotis Korantzopoulos, Konstantinos Siogas
British Journal of Clinical Pharmacology

Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study

British Journal of Clinical PharmacologyMay 21, 2004
Dominique DeplanqueSAFE II Investigators
© 2020 Meta ULC. All rights reserved

Safety considerations in the pharmacological management of atrial fibrillation

International Journal of Cardiology

Jan 15, 2008

A John Camm

PMID: 18191470

DOI: 10.1016/j.ijcard.2007.11.006

Abstract

The pharmacological management of atrial fibrillation (AF) requires careful consideration from a safety perspective. This article focuses primarily on maintenance therapy using antiarrhythmic drugs (AADs). The foremost safety issue for AADs is the propensity of class IA and III agents t...read more

Mentioned in this Paper

Ventricular Fibrillation
Azimilide
Calcium [EPC]
Meta-Analysis (Publications)
Creatinine Clearance Measurement
Disopyramide
Bradycardia
Enzymes, antithrombotic
Calcium
Amiodarone

Similar Papers Found In These Feeds

Supraventricular Arrhythmias

Supraventricular arrhythmias are abnormal heart rhythms, typically faster than normal rhythms, that originate in the upper part of the heart. Find the latest research on supraventricular arrhythmias here.

Coronary Artery Disease

Coronary artery disease is extremely prevalent in western societies and is the number one cause of morbidity and mortality industrialized countries. Known risk factors include hypertension, smoking and dyslipidemia. Discover the latest research on coronary artery disease here.

Related Papers

The New England Journal of Medicine

Drug-induced prolongation of the QT interval

The New England Journal of MedicineJune 18, 2004
Panagiotis Korantzopoulos, Konstantinos Siogas
British Journal of Clinical Pharmacology

Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study

British Journal of Clinical PharmacologyMay 21, 2004
Dominique DeplanqueSAFE II Investigators
Paper Details
References
  • References46
  • Citations32
12345
  • References46
  • Citations32
1234
/papers/safety-considerations-in-the-pharmacological/18191470